Samir Parekh
Medical Oncology · Icahn School of Medicine at Mount Sinai
Credentials: · · · ·
History
KJ Somaiya Medical College
Research
An inflammatory cytokine signature predicts COVID-19 severity and survival
Nature Medicine · 2020 · 2,039 citations
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
New England Journal of Medicine · 2019 · 537 citations
Blood Cancer Journal · 2022 · 266 citations
72 papers
45 papers
45 papers
36 papers
33 papers
- DM
29 papers
22 papers · 3 as a fellow
- OO
22 papers · 13 as a fellow
Grants
- 2015–2030
The Tisch Cancer Institute - Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $41.5K · Icahn School of Medicine at Mount Sinai
- 2025–2030
Developing Lysine Methyltransferase SETD8 Selective Inhibitors for Treating Multiple Myeloma
National Cancer Institute · R01
PI · $1.4M · Icahn School of Medicine at Mount Sinai
- 2023–2027
National Cancer Institute · UH3
PI · $1.1M · Icahn School of Medicine at Mount Sinai
- 2020–2026
Development of a Multi-Omic Clinical Decision Platform to Guide Personalized Therapy
National Cancer Institute · R01
Contact PI · $2.8M · Icahn School of Medicine at Mount Sinai
Clinical trials
- 2026–2029
Principal investigator · Recruiting
Icahn School of Medicine at Mount Sinai
- 2023–2026
Principal investigator · Active not recruiting · Early phase 1
Icahn School of Medicine at Mount Sinai
- 2010–2013
Principal investigator · Terminated · Phase 2
Amit Verma
- 2009–2011
Principal investigator · Completed · Phase 2
Chroma Therapeutics